Central nervous system involvement by mantle cell lymphoma

Nicole McLaughlin; Yucai Wang; Thomas Witzig; Jose (J.C.) Villasboas Bisneto; Thomas Habermann; David Inwards; Nora Bennani; Gita Thanarajasingam; Grzegorz Nowakowski; Luis Porrata; Carrie A Thompson; Ivana Micallef; Patrick Bruce Johnston; Stephen Ansell; Jonas Paludo

doi:10.1080/10428194.2022.2148211

Central nervous system involvement by mantle cell lymphoma

Nicole McLaughlin, Yucai Wang, Thomas Witzig, Jose (J.C.) Villasboas Bisneto, Thomas Habermann, David Inwards, Nora Bennani, Gita Thanarajasingam, Grzegorz Nowakowski, Luis Porrata, Carrie A Thompson, Ivana Micallef, Patrick Bruce Johnston, Stephen Ansell, Jonas Paludo

Hematology

Research output: Contribution to journal › Article › peer-review

Abstract

Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement compared to 72 matched control MCL patients without CNS involvement. Four patients (11%) with CNS MCL were diagnosed with CNS involvement at time of MCL diagnosis. Median OS from MCL diagnosis was 50.3 months (95% CI: 22.8–79.6) for the CNS MCL group compared to 97.1 months (95% CI: 82.8–NR; p= <0.001) for the control group. Median OS from CNS involvement was 4.7 months (95% CI: 2.3–6.7). CNS involvement by MCL has dismal outcomes as evident by a short median OS and PFS after CNS involvement. Advanced stage, blastoid variant, elevated LDH, and elevated Ki67 at MCL diagnosis were features more commonly seen in the CNS MCL cohort.

Original language	English (US)
Journal	Leukemia and Lymphoma
DOIs	https://doi.org/10.1080/10428194.2022.2148211
State	Accepted/In press - 2022

Keywords

brain
BTK inhibitors
Non-Hodgkin lymphoma
treatment

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1080/10428194.2022.2148211

Cite this

McLaughlin, N., Wang, Y., Witzig, T., Villasboas Bisneto, J., Habermann, T., Inwards, D., Bennani, N., Thanarajasingam, G., Nowakowski, G., Porrata, L., Thompson, C. A., Micallef, I., Johnston, P. B., Ansell, S., & Paludo, J. (Accepted/In press). Central nervous system involvement by mantle cell lymphoma. Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2022.2148211

@article{b67e9675243345728250dea510980c99,

title = "Central nervous system involvement by mantle cell lymphoma",

abstract = "Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement compared to 72 matched control MCL patients without CNS involvement. Four patients (11%) with CNS MCL were diagnosed with CNS involvement at time of MCL diagnosis. Median OS from MCL diagnosis was 50.3 months (95% CI: 22.8–79.6) for the CNS MCL group compared to 97.1 months (95% CI: 82.8–NR; p= <0.001) for the control group. Median OS from CNS involvement was 4.7 months (95% CI: 2.3–6.7). CNS involvement by MCL has dismal outcomes as evident by a short median OS and PFS after CNS involvement. Advanced stage, blastoid variant, elevated LDH, and elevated Ki67 at MCL diagnosis were features more commonly seen in the CNS MCL cohort.",

keywords = "brain, BTK inhibitors, Non-Hodgkin lymphoma, treatment",

author = "Nicole McLaughlin and Yucai Wang and Thomas Witzig and {Villasboas Bisneto}, {Jose (J.C.)} and Thomas Habermann and David Inwards and Nora Bennani and Gita Thanarajasingam and Grzegorz Nowakowski and Luis Porrata and Thompson, {Carrie A} and Ivana Micallef and Johnston, {Patrick Bruce} and Stephen Ansell and Jonas Paludo",

note = "Publisher Copyright: {\textcopyright} 2022 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2022",

doi = "10.1080/10428194.2022.2148211",

language = "English (US)",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Central nervous system involvement by mantle cell lymphoma

AU - McLaughlin, Nicole

AU - Wang, Yucai

AU - Witzig, Thomas

AU - Villasboas Bisneto, Jose (J.C.)

AU - Habermann, Thomas

AU - Inwards, David

AU - Bennani, Nora

AU - Thanarajasingam, Gita

AU - Nowakowski, Grzegorz

AU - Porrata, Luis

AU - Thompson, Carrie A

AU - Micallef, Ivana

AU - Johnston, Patrick Bruce

AU - Ansell, Stephen

AU - Paludo, Jonas

PY - 2022

Y1 - 2022

N2 - Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement compared to 72 matched control MCL patients without CNS involvement. Four patients (11%) with CNS MCL were diagnosed with CNS involvement at time of MCL diagnosis. Median OS from MCL diagnosis was 50.3 months (95% CI: 22.8–79.6) for the CNS MCL group compared to 97.1 months (95% CI: 82.8–NR; p= <0.001) for the control group. Median OS from CNS involvement was 4.7 months (95% CI: 2.3–6.7). CNS involvement by MCL has dismal outcomes as evident by a short median OS and PFS after CNS involvement. Advanced stage, blastoid variant, elevated LDH, and elevated Ki67 at MCL diagnosis were features more commonly seen in the CNS MCL cohort.

AB - Involvement of the central nervous system (CNS) is a rare complication of mantle cell lymphoma (MCL) with limited treatment options. We report the outcomes of 36 patients with CNS involvement compared to 72 matched control MCL patients without CNS involvement. Four patients (11%) with CNS MCL were diagnosed with CNS involvement at time of MCL diagnosis. Median OS from MCL diagnosis was 50.3 months (95% CI: 22.8–79.6) for the CNS MCL group compared to 97.1 months (95% CI: 82.8–NR; p= <0.001) for the control group. Median OS from CNS involvement was 4.7 months (95% CI: 2.3–6.7). CNS involvement by MCL has dismal outcomes as evident by a short median OS and PFS after CNS involvement. Advanced stage, blastoid variant, elevated LDH, and elevated Ki67 at MCL diagnosis were features more commonly seen in the CNS MCL cohort.

KW - brain

KW - BTK inhibitors

KW - Non-Hodgkin lymphoma

KW - treatment

UR - http://www.scopus.com/inward/record.url?scp=85142380736&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142380736&partnerID=8YFLogxK

U2 - 10.1080/10428194.2022.2148211

DO - 10.1080/10428194.2022.2148211

M3 - Article

AN - SCOPUS:85142380736

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -

Central nervous system involvement by mantle cell lymphoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this